FDA panel unanimously backs Moderna’s mRNA flu vaccine approval
A federal advisory committee voted 9–0 to recommend Moderna’s mRNA-based flu vaccine after reviewing robust clinical data. The move follows a rare internal dispute at the FDA over vaccine review protocols.